Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293109 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
A Phase 1 study, sponsored by Mehrdad Abedi, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02293109 is a Phase 1 study that has completed, run by Mehrdad Abedi, MD. The registered enrollment target is 10 participants.
The verdict
NCT02293109, a Phase 1 study, has completed, sponsored by Mehrdad Abedi, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib with combination chemotherapy may kill more cancer cells.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG carfilzomib
- DRUG doxorubicin hydrochloride
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2018-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02293109
The ClinicalTrials.gov registry entry for NCT02293109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mehrdad Abedi, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT02293109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02293109 about?
NCT02293109 is a clinical study titled "Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma". This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblasti...
What is the current status of trial NCT02293109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-12-17. Estimated completion is 2018-01-11.
What interventions are being tested in trial NCT02293109?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), carfilzomib (DRUG), doxorubicin hydrochloride (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT02293109?
This trial is sponsored by Mehrdad Abedi, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.